vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and KLA Corporation (KLAC). Click either name above to swap in a different company.

KLA Corporation is the larger business by last-quarter revenue ($3.3B vs $1.6B, roughly 2.0× Edwards Lifesciences). KLA Corporation runs the higher net margin — 34.7% vs 23.1%, a 11.7% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 7.2%). Over the past eight quarters, KLA Corporation's revenue compounded faster (18.2% CAGR vs 9.7%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

KLA Corporation is an American company based in Milpitas, California that makes wafer fab equipment. It supplies process control and yield management systems for the semiconductor industry and other related nanoelectronics industries. The company's products and services are intended for all phases of wafer, reticle, integrated circuit (IC) and packaging production, from research and development to final volume manufacturing.

EW vs KLAC — Head-to-Head

Bigger by revenue
KLAC
KLAC
2.0× larger
KLAC
$3.3B
$1.6B
EW
Growing faster (revenue YoY)
EW
EW
+9.5% gap
EW
16.7%
7.2%
KLAC
Higher net margin
KLAC
KLAC
11.7% more per $
KLAC
34.7%
23.1%
EW
Faster 2-yr revenue CAGR
KLAC
KLAC
Annualised
KLAC
18.2%
9.7%
EW

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
EW
EW
KLAC
KLAC
Revenue
$1.6B
$3.3B
Net Profit
$380.7M
$1.1B
Gross Margin
78.0%
61.4%
Operating Margin
1.8%
Net Margin
23.1%
34.7%
Revenue YoY
16.7%
7.2%
Net Profit YoY
6.8%
39.0%
EPS (diluted)
$0.66
$8.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
KLAC
KLAC
Q1 26
$1.6B
Q4 25
$1.6B
$3.3B
Q3 25
$1.6B
$3.2B
Q2 25
$1.5B
$3.2B
Q1 25
$1.4B
$3.1B
Q4 24
$1.4B
$3.1B
Q3 24
$1.4B
$2.8B
Q2 24
$1.4B
$2.6B
Net Profit
EW
EW
KLAC
KLAC
Q1 26
$380.7M
Q4 25
$91.2M
$1.1B
Q3 25
$291.1M
$1.1B
Q2 25
$333.2M
$1.2B
Q1 25
$358.0M
$1.1B
Q4 24
$385.6M
$824.5M
Q3 24
$3.1B
$945.9M
Q2 24
$366.3M
$836.4M
Gross Margin
EW
EW
KLAC
KLAC
Q1 26
78.0%
Q4 25
78.1%
61.4%
Q3 25
77.8%
61.3%
Q2 25
77.5%
62.0%
Q1 25
78.7%
61.6%
Q4 24
78.9%
60.3%
Q3 24
80.6%
59.6%
Q2 24
79.9%
60.7%
Operating Margin
EW
EW
KLAC
KLAC
Q1 26
1.8%
Q4 25
9.6%
Q3 25
19.8%
Q2 25
26.8%
41.9%
Q1 25
27.9%
41.3%
Q4 24
22.6%
31.6%
Q3 24
25.9%
38.0%
Q2 24
26.8%
36.8%
Net Margin
EW
EW
KLAC
KLAC
Q1 26
23.1%
Q4 25
5.8%
34.7%
Q3 25
18.7%
34.9%
Q2 25
21.7%
37.9%
Q1 25
25.3%
35.5%
Q4 24
27.8%
26.8%
Q3 24
226.7%
33.3%
Q2 24
26.7%
32.6%
EPS (diluted)
EW
EW
KLAC
KLAC
Q1 26
$0.66
Q4 25
$0.16
$8.68
Q3 25
$0.50
$8.47
Q2 25
$0.56
$9.04
Q1 25
$0.61
$8.16
Q4 24
$0.65
$6.16
Q3 24
$5.13
$7.01
Q2 24
$0.61
$6.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
KLAC
KLAC
Cash + ST InvestmentsLiquidity on hand
$2.5B
Total DebtLower is stronger
$5.9B
Stockholders' EquityBook value
$5.5B
Total Assets
$16.7B
Debt / EquityLower = less leverage
1.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
KLAC
KLAC
Q1 26
Q4 25
$4.2B
$2.5B
Q3 25
$3.8B
$1.9B
Q2 25
$4.1B
$2.1B
Q1 25
$3.9B
$1.9B
Q4 24
$4.0B
$1.8B
Q3 24
$4.4B
$2.0B
Q2 24
$2.0B
$2.0B
Total Debt
EW
EW
KLAC
KLAC
Q1 26
Q4 25
$5.9B
Q3 25
$5.9B
Q2 25
$5.9B
Q1 25
$5.9B
Q4 24
$5.9B
Q3 24
$5.9B
Q2 24
$5.9B
Stockholders' Equity
EW
EW
KLAC
KLAC
Q1 26
Q4 25
$10.3B
$5.5B
Q3 25
$10.2B
$5.0B
Q2 25
$10.5B
$4.7B
Q1 25
$10.1B
$4.0B
Q4 24
$10.0B
$3.6B
Q3 24
$9.5B
$3.6B
Q2 24
$7.4B
$3.4B
Total Assets
EW
EW
KLAC
KLAC
Q1 26
Q4 25
$13.7B
$16.7B
Q3 25
$13.3B
$16.3B
Q2 25
$13.5B
$16.1B
Q1 25
$13.0B
$15.2B
Q4 24
$13.1B
$15.0B
Q3 24
$13.0B
$15.7B
Q2 24
$10.1B
$15.4B
Debt / Equity
EW
EW
KLAC
KLAC
Q1 26
Q4 25
1.08×
Q3 25
1.18×
Q2 25
1.25×
Q1 25
1.47×
Q4 24
1.64×
Q3 24
1.65×
Q2 24
1.75×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
KLAC
KLAC
Operating Cash FlowLast quarter
$1.4B
Free Cash FlowOCF − Capex
$1.3B
FCF MarginFCF / Revenue
38.3%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$4.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
KLAC
KLAC
Q1 26
Q4 25
$450.9M
$1.4B
Q3 25
$573.7M
$1.2B
Q2 25
$290.2M
$1.2B
Q1 25
$280.4M
$1.1B
Q4 24
$-127.5M
$849.5M
Q3 24
$351.8M
$995.2M
Q2 24
$371.5M
$892.6M
Free Cash Flow
EW
EW
KLAC
KLAC
Q1 26
Q4 25
$353.5M
$1.3B
Q3 25
$516.2M
$1.1B
Q2 25
$240.9M
$1.1B
Q1 25
$224.4M
$990.0M
Q4 24
$-177.3M
$757.2M
Q3 24
$299.9M
$934.8M
Q2 24
$286.1M
$831.9M
FCF Margin
EW
EW
KLAC
KLAC
Q1 26
Q4 25
22.5%
38.3%
Q3 25
33.2%
33.2%
Q2 25
15.7%
33.5%
Q1 25
15.9%
32.3%
Q4 24
-12.8%
24.6%
Q3 24
22.1%
32.9%
Q2 24
20.9%
32.4%
Capex Intensity
EW
EW
KLAC
KLAC
Q1 26
Q4 25
6.2%
3.2%
Q3 25
3.7%
3.0%
Q2 25
3.2%
3.2%
Q1 25
4.0%
2.7%
Q4 24
3.6%
3.0%
Q3 24
3.8%
2.1%
Q2 24
6.2%
2.4%
Cash Conversion
EW
EW
KLAC
KLAC
Q1 26
Q4 25
4.94×
1.19×
Q3 25
1.97×
1.04×
Q2 25
0.87×
0.97×
Q1 25
0.78×
0.99×
Q4 24
-0.33×
1.03×
Q3 24
0.11×
1.05×
Q2 24
1.01×
1.07×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EW
EW

Segment breakdown not available.

KLAC
KLAC

Wafer Inspection$1.6B48%
Services$786.1M24%
Patterning$696.2M21%
Specialty Semiconductor Process$121.6M4%
PCB And Component Inspection$80.3M2%
Other Revenue$40.2M1%

Related Comparisons